Affinia Therapeutics
OverviewSuggest Edit
Affinia Therapeutics is a biotech company. It develops transformative gene therapies for devastating diseases.
| Type | Private | |
| Founded | 2019 | |
| HQ | Waltham, MA, US | Map |
| Website | affiniatx.com |
Recent NewsAll News
- Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy
- Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
- Affinia Therapeutics Closes $110 Million Series B Financing
- Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
Latest Updates
| Employees (est.) (Jul 2021) | 57 | (+8%) |
| Cybersecurity rating | C | More |
Affinia Therapeutics Office Locations
Affinia Therapeutics has an office in Waltham
Waltham, MA, US (HQ)
100 Beaver St
Affinia Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2019 |
Affinia Therapeutics total Funding | $60 m |
Affinia Therapeutics latest funding size | $60 m |
Time since last funding | a year ago |
Affinia Therapeutics investors | New Enterprise Associates, Atlas Venture, Partners Innovation Fund, Lonza Group, Alexandria Venture Investments, F-Prime Capital |
Affinia Therapeutics's latest funding round in March 2020 was reported to be $60 m. In total, Affinia Therapeutics has raised $60 m
Affinia Therapeutics Cybersecurity Score
Affinia Therapeutics Online and Social Media Presence
Affinia Therapeutics's Trends
Affinia Therapeutics News and Updates
July 20, 2021
Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy
– Botond Roska, M.D., Ph.D., world-renowned scientist and Director at IOB and scientific co-founder of Affinia Therapeutics, will oversee collaboration –
May 13, 2021
Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
Data shows multiple vectors with superiority to AAV9 in CNS, systemic approaches to target muscle while detargeting liver, and improvements in manufacturability Data shows multiple vectors with superiority to AAV9 in CNS, systemic approaches to target muscle while detargeting liver, and improvements…
May 03, 2021
Affinia Therapeutics Closes $110 Million Series B Financing
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110…
February 17, 2021
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
-- Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer -- -- Gene therapy development expert Petra Kaufmann, M.D., joins as chief medical officer –
Affinia Therapeutics Frequently Asked Questions
When was Affinia Therapeutics founded?
Affinia Therapeutics was founded in 2019.
How many employees does Affinia Therapeutics have?
Affinia Therapeutics has 57 employees.
Who are Affinia Therapeutics competitors?
Competitors of Affinia Therapeutics include Oxford BioTherapeutics, MicrofluidX and Stealth BioTherapeutics.
Where is Affinia Therapeutics headquarters?
Affinia Therapeutics headquarters is located at 100 Beaver St, Waltham.
Where are Affinia Therapeutics offices?
Affinia Therapeutics has an office in Waltham.
How many offices does Affinia Therapeutics have?
Affinia Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies